NASDAQ:MLNT - Melinta Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.10 -0.95 (-10.50 %)
(As of 06/18/2018 04:00 PM ET)
Previous Close$9.05
Today's Range$7.70 - $8.95
52-Week Range$5.20 - $24.25
Volume549,500 shs
Average Volume265,309 shs
Market Capitalization$283.89 million
P/E Ratio-0.37
Dividend YieldN/A

About Melinta Therapeutics (NASDAQ:MLNT)

Melinta Therapeutics logoMelinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP. The company also develops Baxdela that in a Phase III clinical trial for treating community-acquired bacterial pneumonia (CABP)); Fusidic Acid, which is in Phase III clinical trial for treating ABSSSIs; and radezolid, a melinta molecule that is in Phase II clinical trial for dermatological applications, as well as ESKAPE pathogen program, which is in preclinical stage targeting superbugs. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals, Inc. and changed its name to Melinta Therapeutics, Inc. in October 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut.

Receive MLNT News and Ratings via Email

Sign-up to receive the latest news and ratings for MLNT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.53
Current Ratio1.48
Quick Ratio1.20


Trailing P/E Ratio-0.37
Forward P/E Ratio-1.78
P/E GrowthN/A

Sales & Book Value

Annual Sales$33.86 million
Price / Sales7.50
Cash FlowN/A
Price / CashN/A
Book Value$2.31 per share
Price / Book3.51


EPS (Most Recent Fiscal Year)($21.86)
Net Income$-58,910,000.00
Net Margins-327.21%
Return on Equity-49.88%
Return on Assets-28.93%


Outstanding Shares31,370,000

Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions

What is Melinta Therapeutics' stock symbol?

Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."

How were Melinta Therapeutics' earnings last quarter?

Melinta Therapeutics (NASDAQ:MLNT) posted its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.95) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.27) by $0.32. The biotechnology company had revenue of $14.84 million for the quarter, compared to analyst estimates of $13.13 million. Melinta Therapeutics had a negative net margin of 327.21% and a negative return on equity of 49.88%. View Melinta Therapeutics' Earnings History.

When is Melinta Therapeutics' next earnings date?

Melinta Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Melinta Therapeutics.

What price target have analysts set for MLNT?

7 brokers have issued 12 month price targets for Melinta Therapeutics' shares. Their predictions range from $2.00 to $8.00. On average, they anticipate Melinta Therapeutics' share price to reach $4.20 in the next twelve months. View Analyst Ratings for Melinta Therapeutics.

Are investors shorting Melinta Therapeutics?

Melinta Therapeutics saw a drop in short interest in May. As of May 31st, there was short interest totalling 1,329,597 shares, a drop of 28.4% from the May 15th total of 1,857,164 shares. Based on an average daily volume of 894,565 shares, the days-to-cover ratio is presently 1.5 days. Currently, 3.9% of the company's stock are sold short.

Who are some of Melinta Therapeutics' key competitors?

Who are Melinta Therapeutics' key executives?

Melinta Therapeutics' management team includes the folowing people:
  • Dr. Erin M. Duffy Ph.d., Chief Scientific Officer (Age 50)
  • Mr. Daniel Mark Wechsler, Pres & CEO (Age 50)
  • Dr. Thomas A. Steitz Ph.D., Co-Founder
  • Dr. Peter B. Moore Ph.D., Co-Founder
  • Dr. William L. Jorgensen Ph.D., Co-Founder

Has Melinta Therapeutics been receiving favorable news coverage?

News coverage about MLNT stock has been trending somewhat positive on Monday, Accern Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Melinta Therapeutics earned a media sentiment score of 0.05 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 47.46 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Melinta Therapeutics' major shareholders?

Melinta Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vatera Holdings LLC (27.86%), BlackRock Inc. (2.74%), Dimensional Fund Advisors LP (1.52%), Millennium Management LLC (1.42%), Sphera Funds Management LTD. (0.78%) and Northern Trust Corp (0.53%). Company insiders that own Melinta Therapeutics stock include David N Gill, Dov A Md Goldstein, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Institutional Ownership Trends for Melinta Therapeutics.

Which institutional investors are selling Melinta Therapeutics stock?

MLNT stock was sold by a variety of institutional investors in the last quarter, including A.R.T. Advisors LLC and Gabelli Funds LLC. View Insider Buying and Selling for Melinta Therapeutics.

Which institutional investors are buying Melinta Therapeutics stock?

MLNT stock was purchased by a variety of institutional investors in the last quarter, including Vatera Holdings LLC, BlackRock Inc., Millennium Management LLC, Stifel Financial Corp, Eversept Partners LLC, Northern Trust Corp, Dimensional Fund Advisors LP and Sphera Funds Management LTD.. Company insiders that have bought Melinta Therapeutics stock in the last two years include David N Gill, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Insider Buying and Selling for Melinta Therapeutics.

How do I buy shares of Melinta Therapeutics?

Shares of MLNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Melinta Therapeutics' stock price today?

One share of MLNT stock can currently be purchased for approximately $8.10.

How big of a company is Melinta Therapeutics?

Melinta Therapeutics has a market capitalization of $283.89 million and generates $33.86 million in revenue each year. The biotechnology company earns $-58,910,000.00 in net income (profit) each year or ($21.86) on an earnings per share basis. Melinta Therapeutics employs 300 workers across the globe.

How can I contact Melinta Therapeutics?

Melinta Therapeutics' mailing address is 300 GEORGE STREET SUITE 301, NEW HAVEN CT, 06511. The biotechnology company can be reached via phone at 312-767-0291 or via email at [email protected]

MarketBeat Community Rating for Melinta Therapeutics (MLNT)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  397 (Vote Outperform)
Underperform Votes:  265 (Vote Underperform)
Total Votes:  662
MarketBeat's community ratings are surveys of what our community members think about Melinta Therapeutics and other stocks. Vote "Outperform" if you believe MLNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.